Zomedica Pharmaceuticals (ZOM) Receives a Buy from Noble Financial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 07 2025
0mins
Should l Buy ?
Source: Business Insider
Analyst Rating and Performance: Noble Financial analyst Robert LeBoyer maintained a Buy rating on Zomedica Pharmaceuticals with a price target of $0.25, despite his average return being -6.6% and a success rate of 29.30%. The stock currently has a consensus rating of Moderate Buy.
Financial Performance and Insider Activity: Zomedica reported a quarterly revenue of $7 million with a GAAP net loss of $6.7 million, showing an increase in revenue compared to the previous year. Positive insider sentiment is noted as 16 insiders have recently increased their holdings, including COO Anthony K Blair's purchase of 150,000 shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
